IPO Timeline
Broker Results (T-2)
2022-12-08
Some brokers release in afternoon
Grey Market (T-1)
2022-12-09
Afternoon
HKEX Allotment (T-1)
2022-12-09
Evening
Registrar Allotment (T-1)
2022-12-09
Evening
Listing Day (T)
2022-12-12
First day of trading
Company Overview
| Stock Name | 高视医疗 |
|---|---|
| Stock Code | 02407 |
| Company Full Name | 高视医疗 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事眼科醫療器械的研發、制造及銷售。 |
| Listing Date | 2022-12-12 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市東城區東直門南大街11號中匯廣場A座1901室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.gaush.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 51.40 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 48.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 67,179,800 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 5,140 |
| 2 lots | 200 | HK$ 10,280 |
| 3 lots | 300 | HK$ 15,420 |
| 4 lots | 400 | HK$ 20,560 |
| 5 lots | 500 | HK$ 25,700 |
| 6 lots | 600 | HK$ 30,840 |
| 7 lots | 700 | HK$ 35,980 |
| 8 lots | 800 | HK$ 41,120 |
| 9 lots | 900 | HK$ 46,260 |
| 10 lots | 1,000 | HK$ 51,400 |
| 15 lots | 1,500 | HK$ 77,100 |
| 20 lots | 2,000 | HK$ 102,800 |
| 25 lots | 2,500 | HK$ 128,500 |
| 30 lots | 3,000 | HK$ 154,200 |
| 35 lots | 3,500 | HK$ 179,900 |
| 40 lots | 4,000 | HK$ 205,600 |
| 50 lots | 5,000 | HK$ 257,000 |
| 60 lots | 6,000 | HK$ 308,400 |
| 70 lots | 7,000 | HK$ 359,800 |
| 80 lots | 8,000 | HK$ 411,200 |
| 100 lots | 10,000 | HK$ 514,000 |
| 200 lots | 20,000 | HK$ 1,028,000 |
| 300 lots | 30,000 | HK$ 1,542,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 100,000 | HK$ 5,140,000 |
| 1,500 lots | 150,000 | HK$ 7,710,000 |
| 2,000 lots | 200,000 | HK$ 10,280,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 51.4 |
|---|---|
| First Day Open | HK$ 51.2 |
| First Day Change | -90.47% |
| First Day Volume | 521800.0 |
| First Day Turnover | 26102400.0 |
Use of Proceeds
| Use of Proceeds | 1、約38.2%或108.1百萬港元將于上市后兩年內用于提高我們的研發能力及加速我們的專利商業化； 2、約29.0%或82.1百萬港元將于上市后兩年內用于提高我們的產能及增強我們的制造能力； 3、約9.5%或26.9百萬港元將于上市后兩年內用于透過聘請專門從事眼科醫療器械銷售及營銷的人員； 4、約10.6%或30.0百萬港元將用作我們的營運資金及一般企業用途； 5、約12.7%或36.0百萬港元將用于償還我們就收購泰靚所產生利率為5%的夾層融資貸款。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
摩根士丹利亚洲有限公司 CE AAD291
海通国际资本有限公司 CE ADQ859
Overall Coordinators (2)
摩根士丹利亚洲有限公司 CE AAD291
海通国际证券有限公司 CE AAF806
Joint Bookrunners (5)
摩根士丹利亚洲有限公司 CE AAD291
海通国际证券有限公司 CE AAF806
大和资本市场香港有限公司 CE AAB639
富途证券国际（香港）有限公司 CE AZT137
老虎证券（香港）环球有限公司 CE BMU940
Joint Lead Managers (7)
摩根士丹利亚洲有限公司 CE AAD291
海通国际证券有限公司 CE AAF806
大和资本市场香港有限公司 CE AAB639
富途证券国际（香港）有限公司 CE AZT137
老虎证券（香港）环球有限公司 CE BMU940
迈时资本有限公司 CE BNO600
SINOMAX SECURITIES LIMITED CE AHC207
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | CL Kiwi Holding Ltd. | 39,135,960 HKD | — | 5.83% | — | 6 months | 2023-06-12 |
| 2 | 江苏中德服贸产业投资基金(有限合伙) | 15,260,660 HKD | — | 2.27% | — | 6 months | 2023-06-12 |
| 3 | 无锡高视创业投资合伙企业(有限合伙) | 7,432,440 HKD | — | 1.11% | — | 6 months | 2023-06-12 |
| 4 | 无锡视高股权投资合伙企业(有限合伙) | 262,217,100 HKD | — | 39.04% | — | 6 months | 2023-06-12 |
Directors & Management
| Chairman | 高鐵塔 |
|---|---|
| Company Secretary | 張博;梁瑞冰 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 高鐵塔(42.76%);Orbimed Asia Partners III, L.P.(12.19%);Cuprite Gem Investments Ltd(7.69%) |
|---|
Subscription Tiers
IPO Timeline
